Akruti Amol Ingole¹, Anjali Vijay Petle², Surbhi Balwant Dhoke³, Piyush Jagdish Balgote⁴, Anirban Goutam Mukherjee⁵ and Uddesh Ramesh Wanjari³*

¹Department of Biotechnology, Priyadarshini Institute of Engineering and Technology, Nagpur, Maharashtra, India
²Department of Biochemistry, RTM Nagpur University, Nagpur, Maharashtra, India
³Department of Biochemistry, Kamla Nehru Mahavidyalaya, Nagpur, Maharashtra, India
⁴Molecular Biology and Genetic Engineering, RTM Nagpur University, Nagpur, Maharashtra, India
⁵Department of Biosciences, School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India

*Corresponding Author: Uddesh Ramesh Wanjari, Department of Biochemistry, Kamla Nehru Mahavidyalaya, Nagpur, Maharashtra, India.

Received: August 13, 2021; Published: August 19, 2021

Abstract

The body system is dependent on each other through communication, cancer development can be supported by the new cancer-induced pathological systemic networks (CISPN), and the entire organism is “cancerized.” The significant anomaly in the transition of epithelial cells to mesenchymal cells plays a vital role in neural crest migration. The metastatic program follows a transformed cellular communication process that, activated once, causes dispersed tumors at a distance from the original site. This review aims to provide an idea of various systemic and new hallmarks and several altered networking processes that eventually end up causing cancer.

Keywords: Cancer; Hallmarks; Inflammation; Cytokines; Tumor

References

1. Paul D. “The systemic hallmarks of cancer”. Journal of Cancer Metastasis and Treatment 6 (2020).
2. Zhong Z., et al. “Wnts and the hallmarks of cancer”. Cancer and Metastasis Reviews3 (2020): 625-645.
3. Senga SS and Grose RP. “Hallmarks of cancer—the new testament”. Open Biology1 (2021): 200358.
4. Hong WX., et al. “Intratumoral immunotherapy for early-stage solid tumors”. Clinical Cancer Research13 (2020): 3091-3099.
5. McAllister SS and Weinberg RA. “The tumor-induced systemic environment as a critical regulator of cancer progression and metastasis”. Nature Cell Biology8 (2014): 717-727.
6. Dudás J., et al. “Epithelial to mesenchymal transition: A mechanism that fuels cancer radio/chemoresistance”. Cells2 (2020): 428.
7. Vincent MD. “The animal within: carcinogenesis and the clonal evolution of cancer cells are speciation events sensu stricto”. Evolution 4 (2010): 1173-1183.
8. Gooding AJ and Schiemann WP. “Epithelial–mesenchymal transition programs and cancer stem cell phenotypes: mediators of breast cancer therapy resistance”. Molecular Cancer Research9 (2020): 1257-1270.
9. Flanigan RC and Yonover PM. “The role of radical nephrectomy in metastatic renal cell carcinoma”. Seminar on Urology and Oncology 2 (2001): 98-102.
10. Kaplan RN., et al. “VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche”. Nature7069 (2005): 820-827.
11. Guo L and Guo N. “Exosomes: Potent regulators of tumor malignancy and potential bio-tools in clinical application”. Critical Reviews in Oncology/Hematology 3 (2015): 346-358.
12. Grivennikov SI., et al. “Immunity, inflammation, and cancer”. Cell 6 (2010): 883-899.
13. Nishida J., et al. “Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis”. Nature Cell Biology4 (2020): 465-475.
14. Tisdale MJ. “Mechanisms of cancer cachexia”. Physiology Review2 (2009): 381-410.
15. Fearon KC., et al. “Cancer cachexia: mediators, signaling, and metabolic pathways”. Cell Metabolism2 (2012): 153-166.
16. Porporato PE. “Understanding cachexia as a cancer metabolism syndrome”. Oncogenesis2 (2016): e200.
17. Wang F., et al. “The Warburg effect in human pancreatic cancer cells triggers cachexia in athymic mice carrying the cancer cells”. BMC Cancer1 (2018): 1-12.
18. Chasen M., et al. “Immunomodulatory agents for the treatment of cachexia”. Current Opinion in Supportive and Palliative Care 4 (2014): 328-333.
19. Falanga A., et al. “Mechanisms and risk factors of thrombosis in cancer”. Critical Reviews in Oncology/Hematology 118 (2017): 79-83.
20. Versteeg HH., et al. “Inhibition of tissue factor signaling suppresses tumor growth”. Blood1 (2008): 190-199.
21. Jiang SH., et al. “Systemic Regulation of Cancer Development by Neuro-Endocrine-Immune Signaling Network at Multiple Levels”. Frontiers in Cell and Developmental Biology 8 (2020): 1056.
22. Braun TP., et al. “Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis”. Journal of Experimental Medicine 12 (2011): 2449-2463.
23. Yehya AHS., et al. “Angiogenesis: managing the culprits behind tumorigenesis and metastasis”. Medicina 1 (2018): 8.
24. Wang L., et al. “Fbxw11 promotes the proliferation of lymphocytic leukemia cells through the concomitant activation of NF-κB and β-catenin/TCF signaling pathways”. Cell Death and Disease4 (2018): 1-12.
25. de Souza CF., et al. “A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence”. Cell Reports2 (2018): 637-651.
26. Takahashi K and Yamanaka S. “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors”. Cell 126 (2006): 663-676.
27. , et al. “Direct reprogramming by oncogenic Ras and Myc”. Proceedings of the National Academy of Sciences of the United States of America 110.10 (2013): 3937-3942.
28. Müller J., et al. “Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma”. Nature Communication 5 (2014): 5712.
29. Mu P., et al. “SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer”. Science 6320 (2017): 84-88.
30. Li Y., et al. “Compression-induced dedifferentiation of adipocytes promotes tumor progression”. Science Advances 4 (2020): eaax5611.
31. Halim S., et al. “Analysis of cell proliferation and tissue remodelling uncovers a KLF4 activity score associated with poor prognosis in colorectal cancer”. British Journal of Cancer7 (2018): 855-863.
32. Strickland S., et al. “The induction of differentiation in teratocarcinoma stem cells by retinoic acid”. Cell 2 (1978): 393-403.
33. Augimeri G., et al. “Natural and synthetic PPARγ ligands in tumor microenvironment: a new potential strategy against breast cancer”. International Journal of Molecular Sciences24 (2020): 9721.
34. Chen J., et al. “H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs”. Nature Genetics1 (2013): 34-42.
35. Giorda R. “Principles of epigenetics and DNA methylation”. In Developmental Human Behavioral Epigenetics (2020): 3-26.
36. Zhang W., et al. “Global DNA hypomethylation in epithelial ovarian cancer: passive demethylation and association with genomic instability”. Cancers3 (2020): 764.
37. Jankowska S., et al. “Molecular classification of glioblastoma based on immunohistochemical expression of EGFR, PDGFRA, NF1, IDH1, p53 and PTEN proteins”. Polish Journal of Pathology1 (2021): 1-10.
38. Kim KH and Roberts CW. “Targeting EZH2 in cancer”. Nature Medicine2 (2016): 128-134.
39. Sun J., et al. “N-terminal truncated carboxypeptidase E represses E-cadherin expression in lung cancer by stabilizing the Snail-HDAC complex”. American Journal of Cancer Research3 (2020): 925.
40. Jain SU., et al. “Histone H3. 3 G34 mutations promote aberrant PRC2 activity and drive tumor progression”. Proceedings of the National Academy of Sciences44 (2020): 27354-27364.
41. Sasagawa T., et al. “Production of an anti-angiogenic factor sFLT1 is suppressed via promoter hypermethylation of FLT1 gene in choriocarcinoma cells”. BMC Cancer1 (2020): 112.
42. Shabgah AG., et al. “Chemokine CXCL14; a double-edged sword in cancer development”. International Immunopharmacology 97 (2021): 107681.
43. Yoshihama S., et al. “NLRC5/MHC class I transactivator is a target for immune evasion in cancer”. Proceedings of the National Academy of Sciences of the United States of America 21 (2016): 5999-6004.
44. Cirone M. “Cancer cells dysregulate PI3K/AKT/mTOR pathway activation to ensure their survival and proliferation: mimicking them is a smart strategy of gammaherpesviruses”. Critical Reviews in Biochemistry and Molecular Biology (2021): 1-10.
45. Nishida J., et al. “Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis”. Nature Cell Biology4 (2020): 465-475.
46. Hatakeyama M. “Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis”. Cell Host Microbe3 (2014): 306-316.
47. Partecke LI., et al. “Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade”. Pancreatology3 (2016): 423-33.
48. Kamiya A., et al. “Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression”. Nature Neuroscience8 (2019): 1289-1305.
49. Mukherjee AG., et al. “A Review on The Usefulness of Various Eukaryotic Pigments and Metabolites in Cancer Treatment”. WJPR10 (2020): 587-611.
50. Mukherjee AG., et al. “A Review on the Present and Future Aspects of Various Prokaryotic Pigments and Metabolites Demonstrating Anti-Cancerous Properties”. International Journal of Engineering Research and Technology7 (2020): 1262-1266.
51. Ingole AA., et al. “A Review on Carcinogenic Heavy Metals”. International Journal of Engineering Research and Technology3 (2021): 403-411.
52. Mukherjee AG and Wanjari U. “A Short Review on Various Aspects of Gene Sequencing and Metagenomics to Study Human Gut Microbiome”. International Research Journal of Engineering and Technology7 (2020): 1280-1284.
53. Mukherjee AG., et al. “The CRISPR-Cas System as a Technology to Redefine Industrial Biotechnology”. Acta Scientific Microbiology6 (2021): 45-52.

Citation

Citation: Ingole, A.A., Petle, A.V., Dhoke, S.B., Balgote, P.J., Mukherjee, A.G., and Wanjari, U.R. “A Review on Systemic and New Cancer Hallmarks”. Acta Scientific Cancer Biology 5.9 (2021): 18-25.

Copyright

Copyright: © 2021 Uddesh Ramesh Wanjari., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.